Corcept Therapeutics Incorporated's relacorilant met the primary endpoint in the phase 3 ROSELLA study for platinum-resistant ovarian cancer patients, boosting shares by over 90% the very same day.
"The interim results demonstrated a highly differentiated clinical profile for TUB-040 in the ADC field, with anti-tumor activity beginning at low doses with a broad therapeutic window that could ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback